Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

Achieve Life Sciences (ACHV) Enterprise Value (2017 - 2026)

Achieve Life Sciences (ACHV) has disclosed Enterprise Value for 17 consecutive years, with -$30.5 million as the latest value for Q1 2026.

  • Quarterly Enterprise Value rose 8.79% to -$30.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$30.5 million through Mar 2026, up 8.79% year-over-year, with the annual reading at -$36.4 million for FY2025, 5.95% down from the prior year.
  • Enterprise Value for Q1 2026 was -$30.5 million at Achieve Life Sciences, up from -$36.4 million in the prior quarter.
  • The five-year high for Enterprise Value was -$12.8 million in Q1 2023, with the low at -$107.9 million in Q2 2024.
  • Average Enterprise Value over 5 years is -$40.1 million, with a median of -$33.4 million recorded in 2025.
  • The sharpest move saw Enterprise Value soared 64.85% in 2023, then crashed 420.4% in 2024.
  • Achieve Life Sciences' Enterprise Value stood at -$22.8 million in 2022, then skyrocketed by 37.37% to -$14.3 million in 2023, then tumbled by 141.09% to -$34.4 million in 2024, then fell by 5.95% to -$36.4 million in 2025, then rose by 16.24% to -$30.5 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Enterprise Value are -$30.5 million (Q1 2026), -$36.4 million (Q4 2025), and -$64.3 million (Q3 2025).